Evaluating the Safety of Intravenous Delivery of Autologous Activated Platelet-rich Plasma

Journal of Health Science Pub Date : 2021-05-25 DOI:10.17532/JHSCI.2021.1276

K. Karina, Krista Ekaputri, J. A. Biben, Ratna Purwoko, T. P. Sibuea, Sarah Listyo Astuti, A. Loho, Yuliardy Limengka, N. ., A. S, Grady Krisandi, Azza Maryam, I. Rosadi, I. Rosliana, S. Sobariah, W. R. Subroto, I. Afini, Tias Widyastuti, A. Zakiyah, D. Ernanda, N. Aini, Jusryanti ., Sulaeha Ad, Sristin Indah Prestiani, Indah Mustika Donna, Habibi ., M. Mutiara

{"title":"Evaluating the Safety of Intravenous Delivery of Autologous Activated Platelet-rich Plasma","authors":"K. Karina, Krista Ekaputri, J. A. Biben, Ratna Purwoko, T. P. Sibuea, Sarah Listyo Astuti, A. Loho, Yuliardy Limengka, N. ., A. S, Grady Krisandi, Azza Maryam, I. Rosadi, I. Rosliana, S. Sobariah, W. R. Subroto, I. Afini, Tias Widyastuti, A. Zakiyah, D. Ernanda, N. Aini, Jusryanti ., Sulaeha Ad, Sristin Indah Prestiani, Indah Mustika Donna, Habibi ., M. Mutiara","doi":"10.17532/JHSCI.2021.1276","DOIUrl":null,"url":null,"abstract":"Introduction: Autologous platelet-rich plasma (PRP) has been a growing trend in the field of medicine due to its broad range of application and is considered safe from bloodborne diseases. Furthermore, various studies have tried to optimize the use of autologous PRP through various preparation protocols, including PRP activation. However, most of the studies available have not evaluated the safety for intravenous delivery of PRP, especially autologous activated PRP (aaPRP). Therefore, this study aimed to evaluate the safety of intravenous delivery of aaPRP. Methods: Blood was drawn from each patient and aaPRP was isolated through calcium activation and light irradiation. Each aaPRP was administered intravenously to all patients. Adverse events were documented and analyzed. Results: Six hundred eleven patients participated in this study with a total of 4244 aaPRP therapies. Quality control of autologous aaPRP showed no platelets present after both calcium activation and light irradiation. No adverse events such as allergic reaction, infection, and coagulation problems were observed on all patients over the course of the study. Conclusion: Our results showed that intravenous administration of autologous aaPRP is safe even in patients with various pathological conditions.","PeriodicalId":15873,"journal":{"name":"Journal of Health Science","volume":"56 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Health Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17532/JHSCI.2021.1276","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 9

Abstract

Introduction: Autologous platelet-rich plasma (PRP) has been a growing trend in the field of medicine due to its broad range of application and is considered safe from bloodborne diseases. Furthermore, various studies have tried to optimize the use of autologous PRP through various preparation protocols, including PRP activation. However, most of the studies available have not evaluated the safety for intravenous delivery of PRP, especially autologous activated PRP (aaPRP). Therefore, this study aimed to evaluate the safety of intravenous delivery of aaPRP. Methods: Blood was drawn from each patient and aaPRP was isolated through calcium activation and light irradiation. Each aaPRP was administered intravenously to all patients. Adverse events were documented and analyzed. Results: Six hundred eleven patients participated in this study with a total of 4244 aaPRP therapies. Quality control of autologous aaPRP showed no platelets present after both calcium activation and light irradiation. No adverse events such as allergic reaction, infection, and coagulation problems were observed on all patients over the course of the study. Conclusion: Our results showed that intravenous administration of autologous aaPRP is safe even in patients with various pathological conditions.

查看原文本刊更多论文

评价静脉输送自体活化富血小板血浆的安全性

自体富血小板血浆(PRP)由于其广泛的应用范围和被认为是安全的血源性疾病，在医学领域已成为一个日益增长的趋势。此外，各种研究试图通过各种制备方案(包括PRP活化)来优化自体PRP的使用。然而，现有的大多数研究尚未评估静脉给药PRP的安全性，特别是自体活化PRP (aaPRP)。因此，本研究旨在评价静脉给药aaPRP的安全性。方法:取患者血，采用钙活化法和光照法分离aaPRP。所有患者均静脉给予aaPRP。记录和分析不良事件。结果:611例患者参与了本研究，共计4244种aaPRP疗法。自体aaPRP经钙活化和光照射后均无血小板出现。在整个研究过程中，所有患者均未观察到过敏反应、感染和凝血问题等不良事件。结论:我们的研究结果表明，即使在各种病理情况下，静脉注射自体aaPRP也是安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Health Science 医学-毒理学

自引率

0.00%

发文量